

# Circular RNA as a biomarker for cancer: A systematic meta-analysis

YULONG LI\*, XIAOLI ZENG\*, JIANXUN HE, YUAN GUI, SONG ZHAO,  
HUA CHEN, QI SUN, NAN JIA and HUI YUAN

Department of Clinical Laboratory, Beijing Anzhen Hospital, Capital Medical University, Beijing 100029, P.R. China

Received September 19, 2017; Accepted June 19, 2018

DOI: 10.3892/ol.2018.9125

**Abstract.** Circular RNAs (circRNAs) may serve as biomarkers for a potentially non-invasive diagnosis of cancer. To understand their diagnostic performance, a systematic meta-analysis of the published literature was conducted to review the diagnostic efficiency of circRNAs in patients with cancer. Eligible studies published up to November 30, 2017, on PubMed and EMBASE, were selected for the meta-analysis. All studies were carefully and independently reviewed by two researchers based on their titles and abstracts, following which full texts were perused for potential eligibility. All statistical analyses were performed by STATA 13.0 statistical software and Meta-DiSc 1.4. A total of 10 eligible studies were included. The pooled diagnostic odds ratio was 7.265. The pooled sensitivity was 0.708 and the pooled specificity was 0.722. The positive likelihood and negative likelihood ratios were 2.483 and 0.372, respectively. The area under the curve was 0.793. circRNA was determined to be a notably effective assistant diagnostic biomarker for cancer.

## Introduction

Cancer is a major public health problem globally. Cancer is a class of diseases that undergoes uncontrollable cell proliferation and differentiation. Based on the 2015 cancer statistics, it is currently the second leading cause of mortality in numerous countries (including China, Europe and the

USA), and is expected to surpass heart diseases as the leading cause of mortality in the near future (1). Although the risk of succumbing to cancer has decreased by ~20% from its maximum in 1991-2011 (1), it must be diagnosed with high sensitivity and specificity in order to determine the appropriate therapy and prognosis. Recently, a number of biomarkers with diagnostic and prognostic potential value have been demonstrated in numerous cancer types, including the tumor markers human epididymis secretory protein 4 and cancer antigen 125 in endometrial (2) and ovarian cancer types (3). Additionally, mutant genes have been used in the selection of an appropriate therapy, including epidermal growth factor receptor mutation in non-small cell lung cancer (4), Kirsten rat sarcoma viral oncogene homolog in colorectal cancer (5) and v-raf murine sarcoma viral oncogene homolog B1 mutation in melanoma (6); however, reliable and convenient biomarkers are required to evaluate the diagnostic and prognostic significance of different cancer types.

Classic biomarkers present with potentially limiting factors, including cost, availability and reproducibility (7). Utility is compromised by different disease heterogeneities, specific genetics and proteomics, and the influence of life-style; therefore, a number of serum or tissue biomarkers, including non-coding RNAs (ncRNAs), have been developed for clinical experiments. ncRNAs have notable potential for future biomarker approaches. Numerous studies have reported the use of ncRNAs, including microRNAs and long ncRNAs (lncRNAs), in the early detection and prognosis of various cancer types (8,9). Previously, a number of studies focused on a novel class of ncRNAs that is endogenously expressed as single-stranded, covalently-closed circular molecules, also known as circular RNAs (circRNAs) (10-12). circRNAs were demonstrated to be antagonists of specific microRNAs by functioning as microRNA sponges (10,13), and they are also known as stable molecules, as demonstrated by their long half-lives in cells (14). These observations resulted in the consideration that circRNAs could serve as potential biomarkers for the non-invasive diagnosis of numerous diseases, including disorders of the central nervous system (15), cancer (16) and a number of forms of cardiovascular diseases (17).

To determine if circRNA could serve as a sensitive and specific biomarker for cancer, a systematic meta-analysis of

---

*Correspondence to:* Professor Hui Yuan, Department of Clinical Laboratory, Beijing Anzhen Hospital, Capital Medical University, 2 Anzhen Road, Beijing 100029, P.R. China  
E-mail: 18911662931@189.cn

\*Contributed equally

**Abbreviations:** circRNAs, circular RNAs; QUADAS, quality assessment of diagnostic accuracy studies; PLR, positive likelihood ratio; NLR, negative likelihood ratio; DOR, diagnostic odds ratio; CI, confidence interval; SROC, summary receiver operator characteristic; AUC, area under the curve

**Key words:** circular RNA, cancer, diagnostic value, meta-analysis

the published literature was performed in the present study, in order to review the diagnostic efficiency of circRNA in patients with cancer from the available data and to identify a novel non-invasive biomarker for cancer diagnosis.

## Materials and methods

**Search strategy.** This meta-analysis was conducted in accordance with the guidelines of diagnostic meta-analysis as follows: Eligible studies published up to November 30, 2017, on PubMed (<https://www.ncbi.nlm.nih.gov/pubmed>) and EMBASE (<https://www.elsevier.com/solutions/embase-biomedical-research>), were selected for the meta-analysis. Non-English studies were excluded. No restriction was placed on the year of publication or publishing status. The key words employed for literature retrieval included the following: 'circular RNA' or 'circRNA', and 'tumor' or 'neoplasm', or 'cancer' or 'carcinoma'. Additionally, the reference lists of eligible articles were manually searched to obtain additional sources.

**Selection of publications.** All studies were carefully and independently reviewed by two researchers based on their titles and abstracts, following which full texts were perused for potential eligibility. Any disagreement was resolved by a full discussion, until consensus was achieved. All publications included in the meta-analysis were required to meet the following criteria: i) Studies should analyze the association between circRNA and patients with any cancer type; ii) studies should contain sensitivity and specificity data (or the possibility of deriving such values from the data); and iii) studies should have enrolled  $\geq 20$  patients and matched controls. Studies were excluded if they involved any of the following parameters: i) Duplicate studies; ii) letters, editorials, meeting abstracts, case reports and reviews; iii) patients and control subjects that did not qualify, in which the patients sample size was low or the disease cannot be defined; iv) studies with missing data, and v) No-English studies. If the same author reported that their results were acquired from overlapping populations, only the first study published or the most complete study was included.

**Data extraction and quality assessment.** The following parameters were collected from each study: Author name, publication year, country and ethnicity, sample type, normalization control, sample size and data for two-by-two tables (sensitivity and specificity). The Quality Assessment of Diagnostic Accuracy Studies (QUADAS) checklist (<http://www.bristol.ac.uk/population-health-sciences/projects/quadas/>) was used to systematically assess the quality of the articles included in the diagnostic meta-analysis. Specifically, 14 items from the QUADAS checklist were applied to each article, and an answer of 'Yes', 'No' or 'Unclear' was determined. Only 'Yes' resulted in a score.

**Statistical analysis.** All statistical analyses were performed using the STATA 13.0 statistical software (StataCorp LLC, TX, USA) and Meta-DiSc 1.4 (Unit of Clinical Biostatistics, Ramón y Cajal Hospital, Madrid, Spain). Data from each study (true-positives, false-positives, true-negatives and

false-negatives) were extracted to obtain the pooled sensitivity, specificity, positive likelihood ratio (PLR), negative likelihood ratio (NLR), diagnostic odds ratio (DOR) and their 95% confidence interval (CI), summary receiver operator characteristic (SROC) curve and area under the curve (AUC), in order to determine the overall performance of the detection method.  $P < 0.05$  (two-sided) was considered to indicate a statistically significant difference. Additionally, heterogeneity across studies was assessed using Cochran's Q and  $I^2$  statistics, where  $I^2 > 50\%$  indicated the existence of significant heterogeneity. Finally, evaluation of the threshold effect (Spearman's rank correlation) and publication bias (funnel plots) were also undertaken.

## Results

**Literature search.** Electronic and manual searches yielded a total of 146 potentially eligible articles. The steps involved in screening the articles for the meta-analysis is depicted as a flow chart in Fig. 1. Screening titles and abstracts resulted in the exclusion of 109 articles. A further 21 articles were excluded following more detailed assessment of the full text. Finally, 10 eligible studies (12 tests) were included in the meta-analysis (18-27).

**Study characteristics.** The characteristics of the 10 eligible studies are summarized in Table I (18-27). A total of 799 patients with different cancer types and adjacent controls were involved in these 12 tests. Assessment using QUADAS indicated that the studies were of high quality, with positive results in 13/14 items (Fig. 2). Additionally, the mean impact factor was calculated to be 2.59.

**Meta-analysis.** Overall, 10 studies involving 799 patients with various cancer types reported the detection performances of circRNA (Table II). The sensitivity of circRNA detection testing ranged from 0.449-0.855, and the reported specificity ranged from 0.450-0.900. The pooled DOR was 7.265 (95% CI, 5.616-9.398;  $Q=12.72$ ;  $P=0.312$ ;  $I^2=13.5\%$ ). The pooled sensitivity was 0.708 (95% CI, 0.676-0.740;  $Q=74.77$ ;  $P<0.001$ ;  $I^2=85.3\%$ ) and the pooled specificity was 0.722 (95% CI, 0.690-0.753;  $Q=60.81$ ;  $P<0.001$ ;  $I^2=81.9\%$ ). The PLR and NLR were 2.483 (95% CI, 2.019-3.054;  $Q=30.83$ ;  $P=0.001$ ;  $I^2=64.3\%$ ) and 0.372 (95% CI, 0.289-0.479;  $Q=44.59$ ;  $P<0.001$ ;  $I^2=75.3\%$ ), respectively. The AUC was 0.793. The forest plots and SROC are depicted in Figs. 3 and 4, respectively.

**Investigation of the threshold effect.** Spearman's rank correlation was also performed to confirm the threshold effect. No indication of a threshold effect was determined in the studies [Spearman's correlation coefficient ( $\rho$ ), 0.340;  $P=0.280$ ]. Additionally, the slope (b) of the regression equation did not differ from zero ( $P=0.852$ ), implying no heterogeneity between the studies.

**Publication bias.** Finally, the presence of a statistically significant slope coefficient ( $P<0.05$ ) was considered to indicate a possible publication bias. Funnel plots were produced (Fig. 5). No publication bias was observed in the included studies ( $P=0.82$ ) and the regression line represented a symmetrical curve.

Table I. Characteristics of 10 studies included in the meta-analysis.

First author	Year	Disease	circRNA used for detection	Case no.	Control no.	Region	TP	FP	FN	TN	IF	(Refs.)
Li <i>et al</i>	2015	Gastric cancer	hsa_circ_002059	101	101	China	82	38	19	63	2.799	(18)
Qin <i>et al</i>	2016	Hepatocellular carcinoma	hsa_circ_0001649	89	89	China	72	28	17	61	1.736	(19)
Wang <i>et al</i>	2015	Colorectal cancer	hsa_circ_001988	31	31	China	21	8	10	23	1.581	(20)
Shang <i>et al</i>	2016	Hepatocellular carcinoma	hsa_circ_0005075	30	30	China	25	3	5	27	2.133	(21)
Chen <i>et al</i>	2017	Gastric cancer	hsa_circ_0000190	104	104	China	75	30	29	74	2.799	(22)
Huang <i>et al</i>	2017	Gastric cancer	hsa_circ_0000745	60	60	China	51	33	9	27	3.365	(23)
Fu <i>et al</i>	2017	Hepatocellular carcinoma	hsa_circ_0003570	107	107	China	48	14	59	93	1.521	(24)
Yin <i>et al</i>	2017	Breast cancer	hsa_circ_0001785	20	20	China	16	5	4	15	2.871	(25)
		Breast cancer	hsa_circ_0108942	20	20	China	16	10	4	10	2.871	
		Breast cancer	hsa_circ_0068033	20	20	China	14	8	6	12	2.871	
Yao <i>et al</i>	2017	Hepatocellular carcinoma	cirZKSCAN1	102	102	China	84	28	18	74	5.314	(26)
Zhao <i>et al</i>	2017	Gastric cancer	hsa_circ_0000181	115	115	China	62	17	53	98	1.521	(27)

TP, true-positive; FP, false-positive; FN, false-negative; TN, true-negative; IF, impact factor; circRNA, circular RNA.




Figure 1. Flow chart of studies included in the meta-analysis following implementation of exclusion criteria.

## Discussion

There are an increasing number of molecular biomarkers, including microRNAs and lncRNAs, being used in cancer diagnostics. circRNAs are widely expressed in human cells (28). Highly conserved sequences and a high degree of stability in mammalian cells are two of their most important properties (10,13); thus, circRNAs have the potential to be ideal biomarkers in the diagnosis of cancer. Numerous studies have evaluated the performance of circRNAs in cancer diagnosis (18-27); however, no systematic evaluation of circRNAs has been performed. The differences in the performances were too large and hence, to the best of our knowledge, the present

Table II. Detection performances of circular RNA reported by 10 studies.

First author	Diagnostic OR (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	Positive LR (95% CI)	Negative LR (95% CI)	(Refs.)
Li <i>et al</i>	7.16 (3.77-13.59)	0.81 (0.72-0.88)	0.62 (0.52-0.72)	2.16 (1.65-2.82)	0.30 (0.20-0.46)	(18)
Qin <i>et al</i>	9.23 (4.62-18.44)	0.81 (0.71-0.88)	0.69 (0.58-0.78)	2.57 (1.86-3.55)	0.28 (0.18-0.44)	(19)
Wang <i>et al</i>	6.04 (2.01-18.17)	0.68 (0.49-0.83)	0.74 (0.55-0.88)	2.63 (1.38-5.00)	0.43 (0.25-0.75)	(20)
Shang <i>et al</i>	45.00 (9.73-208.08)	0.83 (0.65-0.94)	0.90 (0.73-0.98)	8.33 (2.81-24.67)	0.19 (0.08-0.42)	(21)
Chen <i>et al</i>	6.38 (3.49-11.66)	0.72 (0.62-0.80)	0.71 (0.61-0.80)	2.50 (1.81-3.46)	0.39 (0.28-0.55)	(22)
Huang <i>et al</i>	4.64 (1.94-11.09)	0.85 (0.73-0.93)	0.45 (0.32-0.58)	1.55 (1.20-1.99)	0.33 (0.17-0.65)	(23)
Fu <i>et al</i>	5.40 (2.70-53.33)	0.45 (0.35-0.55)	0.87 (0.79-0.93)	3.43 (2.01-5.83)	0.63 (0.53-0.76)	(24)
Yin <i>et al</i>	12.00 (2.70-53.33)	0.80 (0.56-0.94)	0.75 (0.51-0.91)	3.20 (1.45-7.05)	0.27 (0.11-0.66)	(25)
	4.00 (0.98-16.27)	0.80 (0.56-0.94)	0.50 (0.27-0.73)	1.60 (0.98-2.61)	0.40 (0.15-1.07)	
	3.50 (0.94-12.97)	0.70 (0.46-0.88)	0.60 (0.36-0.81)	1.75 (0.95-3.22)	0.50 (0.23-1.07)	
Yao <i>et al</i>	12.33 (6.31-24.09)	0.82 (0.74-0.89)	0.73 (0.63-0.81)	3.00 (2.16-4.16)	0.24 (0.16-0.38)	(26)
Zhao <i>et al</i>	6.74 (3.58-12.69)	0.54 (0.44-0.63)	0.85 (0.77-0.91)	3.65 (2.28-5.84)	0.54 (0.44-0.67)	(27)

OR, odds ratio; LR, likelihood ratio; CI, confidence interval.




Figure 2. Quality assessment of included studies based on the Quality Assessment of Diagnostic Accuracy Studies tool.

study is the first meta-analysis to provide precise and controlled data on the diagnostic performance of circRNAs in cancer.

A total of 10 eligible, high-quality studies were included in the present meta-analysis. The present study demonstrated the varying sensitivities and specificities of circRNAs in the diagnosis of cancer; however, the range of their sensitivity and specificity was large and their diagnostic performance cannot be evaluated. The pooled sensitivity and specificity

were observed to be slightly high (70.8 and 72.2%), which demonstrated that circRNAs could be used as assistant indicators in the diagnosis of cancer. The SROC curve and DOR indicated that circRNAs exhibited a moderate diagnostic performance. The pattern of the data points in the SROC curve did not indicate a 'shoulder-arm' shape, which indicates no threshold effect was determined in these studies, and the AUC of the SROC was 0.793. Cumulatively, these results indicated






Figure 3. Forests plot of the accuracy of circRNAs for the diagnosis of cancer. (A) DOR forest plot of the circRNAs. (B) Sensitivity forest plot of the circRNAs. (C) Specificity forest plot of the circRNAs. (D) Positive LR forest plot of the circRNAs. (E) Negative LR forest plot of the circRNAs. DOR, diagnostic odds ratio; LR, likelihood ratio; circRNAs, circular RNAs; df, degrees of freedom.




Figure 4. SROC of circular RNAs for cancer diagnosis. SROC, summary receiver-operating characteristic; AUC, area under curve; SE, standard error;  $Q^*$ ,  $Q$  statistic.




Figure 5. Funnel plot of the 12 tests in the 10 included studies. DOR, diagnostic odds ratio; ESS, effective sample size.

that circRNA had a moderate level of overall diagnostic accuracy for cancer diagnosis.

In the present study, heterogeneity was not determined in the pooled DOR of the circRNAs ( $P = 0.852$ ). Furthermore,

publication bias and Spearman's rank correlation were also performed. No statistical difference was determined using Spearman's rank correlation, which meant that no threshold effect among these studies was observed. No publication bias was observed either in the included studies.

However, a number of limitations in this meta-analysis should be noted. Firstly, all included studies were reported by Chinese researchers. For this reason, the diagnostic performance of circRNAs may be not be all-sided, in spite of the absence of heterogeneity, threshold effect and publication bias; Therefore, further research regarding circRNAs, particularly in relation to the other countries' projects, as a biomarker in cancer diagnosis is required. Secondly, only the integral diagnostic performance of circRNAs on cancer was evaluated. The performance may be cursory on a specific type of circRNA for specific cancer types. Since the aim of the present study was to evaluate the likelihood of circRNAs performing for the diagnosis of cancer, the integral performance of circRNA in cancer was sufficient. Finally, the moderate levels of circRNA sensitivity and specificity could be attributed to technological, instrumental and staffing limitations; however, there is not sufficient data to evaluate these parameters. The cut-off value of circRNA efficiency in different cancer types remains controversial, and investigating its clinical significance may improve the diagnostic performance of circRNAs.

In conclusion, circRNA is a moderately effective assistant diagnostic biomarker for cancer; however, its diagnostic performance remains to be determined and further research of specific circRNA types for specific cancer types is required in order to determine this.

### Acknowledgements

The authors thank Dr Si Chen (Department of Clinical Laboratory, Beijing Anzhen Hospital) and Dr Chuiwen Deng (Department of Rheumatology and Clinical Immunology, Peking Union Medical College Hospital) who gave positive advice regarding this study.

### Funding

The present study was supported by the Talent Training Project of High Level Health Technology from Beijing Health System (grant no. 2015-3-052) and the National Natural Science Foundation of China (grant no. 81500332).

### Availability of data and materials

All data generated or analyzed during this study are included in this published article.

### Authors' contributions

YL and XZ carried out the conception and design, acquisition of data, analysis of data, and drafting the manuscript. HY performed the acquisition of data, and the drafting and revising of the manuscript. JH and SZ aided with acquisition of data. HC aided with the statistical analysis. QS and NJ participated in the design and coordination of the study and helped to revise the manuscript.

### Ethics approval and consent to participate

Not applicable.

### Patient consent for publication

Not applicable.

### Competing interests

The authors declare that they have no competing interests.

### References

1. Siegel RL, Miller KD and Jemal A: Cancer statistics, 2015. *CA Cancer J Clin* 65: 5-29, 2015.
2. Bian J, Sun X, Li B and Ming L: Clinical significance of serum HE4, CA125, CA724, and CA19-9 in patients with endometrial cancer. *Technol Cancer Res Treat* 16: 435-439, 2017.
3. Karakaya BK, Başer E, Bildacı B, Cömert EÇ, Bayraktar N, Dursun P, Kuşçu E and Ayhan A: Alternative tumor markers in the diagnosis of ovarian cancer. *Ginekol Pol* 87: 565-769, 2016.
4. Brugger W, Triller N, Blasinska-Morawiec M, Curescu S, Sakalauskas R, Manikhas GM, Mazieres J, Whittom R, Ward C, Mayne K, *et al*: Prospective molecular marker analyses of EGFR and KRAS from a randomized, placebo-controlled study of erlotinib maintenance therapy in advanced non-small-cell lung cancer. *J Clin Oncol* 29: 4113-4120, 2011.
5. Van Cutsem E, Köhne CH, Hitre E, Zaluski J, Chang Chien CR, Makhson A, D'Haens G, Pintér T, Lim R, Bodoky G, *et al*: Cetuximab and chemotherapy as initial treatment for metastatic colorectal cancer. *N Engl J Med* 360: 1408-1417, 2009.
6. Gear H, Williams H, Kemp EG and Roberts F: BRAF mutations in conjunctival melanoma. *Invest Ophthalmol Vis Sci* 45: 2484-2488, 2004.
7. Bodzin AS and Busuttil RW: Hepatocellular carcinoma: Advances in diagnosis, management, and long term outcome. *World J Hepatol* 7: 1157-1167, 2015.
8. Hu AX, Huang ZY, Zhang L and Shen J: Potential prognostic long non-coding RNA identification and their validation in predicting survival of patients with multiple myeloma. *Tumour Biol* 39: 1010428317694563, 2017.
9. Song T, Liang Y, Cao Z, Du W and Li Y: Computational analysis of specific MicroRNA biomarkers for noninvasive early cancer detection. *Biomed Res Int* 2017: 4680650, 2017.
10. Hansen TB, Jensen TI, Clausen BH, Bramsen JB, Finsen B, Damgaard CK and Kjems J: Natural RNA circles function as efficient microRNA sponges. *Nature* 495: 384-388, 2013.
11. Bachmayr-Heyda A, Reiner AT, Auer K, Sukhbaatar N, Aust S, Bachleitner-Hofmann T, Mesteri I, Grunt TW, Zeillinger R and Pils D: Correlation of circular RNA abundance with proliferation-exemplified with colorectal and ovarian cancer, idiopathic lung fibrosis, and normal human tissues. *Sci Rep* 5: 8057, 2015.
12. Hansen TB, Kjems J and Damgaard CK: Circular RNA and miR-7 in cancer. *Cancer Res* 73: 5609-5612, 2013.
13. Jeck WR, Sorrentino JA, Wang K, Slevin MK, Burd CE, Liu J, Marzluff WF and Sharpless NE: Circular RNAs are abundant, conserved, and associated with ALU repeats. *RNA* 19: 141-157, 2013.
14. Memczak S, Jens M, Elefsinioti A, Torti F, Krueger J, Rybak A, Maier L, Mackowiak SD, Gregersen LH, Munschauer M, *et al*: Circular RNAs are a large class of animal RNAs with regulatory potency. *Nature* 495: 333-338, 2013.
15. Lukiw WJ: Circular RNA (circRNA) in Alzheimer's disease (AD). *Front Genet* 4: 307, 2013.
16. Li Y, Zheng Q, Bao C, Li S, Guo W, Zhao J, Chen D, Gu J, He X and Huang S: Circular RNA is enriched and stable in exosomes: A promising biomarker for cancer diagnosis. *Cell Res* 25: 981-984, 2015.
17. Burd CE, Jeck WR, Liu Y, Sanoff HK, Wang Z and Sharpless NE: Expression of linear and novel circular forms of an INK4/ARF-associated non-coding RNA correlates with atherosclerosis risk. *PLoS Genet* 6: e1001233, 2010.
18. Li P, Chen S, Chen H, Mo X, Li T, Shao Y, Xiao B and Guo J: Using circular RNA as a novel type of biomarker in the screening of gastric cancer. *Clin Chim Acta* 444: 132-136, 2015.
19. Qin M, Liu G, Huo X, Tao X, Sun X, Ge Z, Yang J, Fan J, Liu L and Qin W: Hsa\_circ\_0001649: A circular RNA and potential novel biomarker for hepatocellular carcinoma. *Cancer Biomark* 16: 161-169, 2016.

20. Wang X, Zhang Y, Huang L, Zhang J, Pan F, Li B, Yan Y, Jia B, Liu H, Li S and Zheng W: Decreased expression of hsa\_circ\_001988 in colorectal cancer and its clinical significances. *Int J Clin Exp Pathol* 8: 16020-16025, 2015.
21. Shang X, Li G, Liu H, Li T, Liu J, Zhao Q and Wang C: Comprehensive circular RNA profiling reveals that hsa\_circ\_0005075, a new circular RNA biomarker, is involved in hepatocellular carcinoma development. *Medicine (Baltimore)* 95: e3811, 2016.
22. Chen S, Li T, Zhao Q, Xiao B and Guo J: Using circular RNA hsa\_circ\_0000190 as a new biomarker in the diagnosis of gastric cancer. *Clin Chim Acta* 466: 167-171, 2017.
23. Huang M, He YR, Liang LC, Huang Q and Zhu ZQ: Circular RNA hsa\_circ\_0000745 may serve as a diagnostic marker for gastric cancer. *World J Gastroenterol* 23: 6330-6338, 2017.
24. Fu L, Wu S, Yao T, Chen Q, Xie Y, Ying S, Chen Z, Xiao B and Hu Y: Decreased expression of hsa\_circ\_0003570 in hepatocellular carcinoma and its clinical significance. *J Clin Lab Anal* 32, 2018.
25. Yin WB, Yan MG, Fang X, Guo JJ, Xiong W and Zhang RP: Circulating circular RNA hsa\_circ\_0001785 acts as a diagnostic biomarker for breast cancer detection. *Clin Chim Acta*: S0009-8981(17)30407-2, 2017.
26. Yao Z, Luo J, Hu K, Lin J, Huang H, Wang Q, Zhang P, Xiong Z, He C, Huang Z, *et al*: ZKSCAN1 gene and its related circular RNA (circZKSCAN1) both inhibit hepatocellular carcinoma cell growth, migration, and invasion but through different signaling pathways. *Mol Oncol* 11: 422-437, 2017.
27. Zhao Q, Chen S, Li T, Xiao B and Zhang X: Clinical values of circular RNA 0000181 in the screening of gastric cancer. *J Clin Lab Anal* 32: e22333, 2018.
28. Salzman J, Gawad C, Wang PL, Lacayo N and Brown PO: Circular RNAs are the predominant transcript isoform from hundreds of human genes in diverse cell types. *PLoS One* 7: e30733, 2012.